Karyopharm faces a precarious financial outlook characterized by a persistent disconnect between its 96.1% gross margins and deeply negative operating margins of -76.3%. The company's reliance on XPOVIO revenue growth, which remains volatile, is insufficient t...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$2.32-69.3% vs -$1.37 | $33M+3.8% vs $32M |
Q2 2026 May 14, 2026 | -$1.24+14.5% vs -$1.45 | $35M+11.7% vs $31M |
Q1 2026 Feb 12, 2026 | -$2.23+1.3% vs -$2.26 | $34M-2.9% vs $35M |
Q4 2025 Nov 3, 2025 | -$3.82-10.1% vs -$3.47 | $44M+4.7% vs $42M |
NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees.
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIOÂ (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis.
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
Benchmark KPTI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Karyopharm Therapeutics Inc. (KPTI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.75 | $39.66M | -0.10 | 0.57% | -134.21% | — | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $3.80 | $241.54M | -3.22 | 0.78% | -8.7% | -31.27% | — | |
| $9.70 | $2.25B | 16.17 | 19.63% | 32.98% | 39.59% | — | |
| $56.00 | $8.57B | 20.22 | 87.32% | 55.22% | 72.3% | — |
Karyopharm Therapeutics Inc. (KPTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Karyopharm Therapeutics Inc. (KPTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 31, 2026·SEC
Aug 13, 2026·SEC
Jul 31, 2026·SEC
Get notified when KPTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Karyopharm Therapeutics Inc. (KPTI) stock FAQ — growth, dividends, profitability & financials explained
Karyopharm Therapeutics Inc. (KPTI) reported $146.6M in revenue for fiscal year 2025. This represents a 96361% increase from $0.2M in 2011.
Karyopharm Therapeutics Inc. (KPTI) grew revenue by 0.6% over the past year. Growth has been modest.
Karyopharm Therapeutics Inc. (KPTI) reported a net loss of $224.7M for fiscal year 2025.
Karyopharm Therapeutics Inc. (KPTI) had negative free cash flow of $65.3M in fiscal year 2025, likely due to heavy capital investments.
